Abstract 54P
Background
There is a paucity of studies on platinum-based chemotherapy in advanced breast cancer (ABC) from developing countries like India.
Methods
This was a retrospective study of patients with ABC who were treated with platinum-based chemotherapy (gemcitabine carboplatin, GC) in a tertiary cancer center in India from Aug 2015 to Nov 2019. Patients were treated with injection gemcitabine 1gm/m2 on D1/D8 and injection carboplatin (AUC 5-6) on D1 for 6 cycles. Patients were assessed clinically before each cycle and by imaging before 4th and after the 6th cycle. Descriptive statistics were used to analyze the baseline characteristics. Survival was estimated with Kaplan Meier’s curve & univariate/multivariate analysis was done using regression analysis.
Results
Baseline characteristics are listed in the table. 34 % & 91 % had metastatic disease at initial presentation and at the start of GC respectively. Repeat biopsy at metastatic disease was done in 37 % & 50 % had the same molecular subtype. Median number of prior lines of systemic therapy for metastatic/progressive disease was 1 (range: 0 to 5). The median number of sites of metastasis was 2 (range: 0 to 6). Patients with visceral crises were 23%. The median number of cycles of GC chemotherapy received was 6 (range: 2 to 6). A dose reduction of chemotherapy was done in 74%.Only 57% patients could complete 6 cycles of chemotherapy. The responses among 34 evaluable patients were complete response (11%), partial response (23%), stable disease (40%) and progressive disease (23%). The hematological toxicities of all grade were seen in 91%, and 68% had grade 3 or 4 hematological toxicity. The median progression-free survival (PFS) and overall survival (OS) was 6 months [95% CI: 3.2-5.7 months] and 8 months [95% CI: 5.3-10.7 months] respectively. The 1-year PFS and OS were 19 % and 34% respectively. Univariate analysis did not show molecular subtype & BRCA status as a significant factor in improving PFS.The number of cycles of GC chemotherapy received ( >/= 3 cycles ) and the Infiltrating Ductal carcinoma histology ( IDC ) was significant in improving PFS, ( HR – 2.4, 95 % CI -1.04-5.67, p value – 0.04 ) & ( HR – 3.23, 95 % CI – 1.47 – 7.06, p value -0.03 ) respectively. Table: 54P
Baseline characteristics
Variable | n (%) |
Age | Mean - 45.5 yrs; (28 – 68 yrs) |
Sex | Female- 34 (97%) Male- 1 (3 %) |
Menopausal Status | Premenopausal – 26 ( 75 %) Postmenopausal – 8 (23 %) |
ECOG PS | 1- 29 (83 % ) 2– 6 (17% ) |
Histology | IDC- 27 (77 % ) Mixed – 6 (17% ) Others - 2 (6 % ) * |
Grade | Grade III -29 ( 83% ) Grade II – 6 (17% ) |
Hormone Receptor Status | Low ER Positive -7 (20 % ) High ER positive- 6 (17% ) ER negative -22 (63 % ) Low PR positive - 5 (14 % ) High PR positive -3 (9 % ) PR negative- 27( 77 % ) |
Her 2 neu | Positive – 6 (17%) Negative –28 (80 % ) Equivocal-1(3 % ) |
BRCA | BRCA 1 – 6 ( 17% ) Negative – 6(17 % ) Not tested – 23 (66% ) |
Molecular Subtypes | Luminal B -13 ( 37% ) Her 2 enriched -3 ( 9 % ) TNBC -19 ( 54% ) |
* 1 metaplastic, 1 Poorly differentiated with neuroendocrine features
Conclusions
This is the largest study from India on platinum-based chemotherapy in ABC. The real-world outcomes with platinum-based chemotherapy in ABC were PFS 6 months and OS 8 months. On multivariate analysis, patients who completed more than 3 cycles of GC chemotherapy had better survival (p value – 0.003, HR – 3.23, 95 % CI, 1.47 -7.06).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
325P - Clinical characteristics and outcomes of cancer patients with COVID-19 infection: A retrospective study in a single center in the Philippines
Presenter: Frances Victoria Que
Session: e-Poster Display Session
326P - Management of diffuse large B cell lymphomas in the COVID-19 era
Presenter: David Ng
Session: e-Poster Display Session
327P - COVID-19 in patients with oncohematologic diseases in Kazakhstan
Presenter: Zaure Dushimova
Session: e-Poster Display Session
328P - Impact of COVID-19 pandemic on 30 days colorectal cancer patients mortality undergoing emergency operation
Presenter: Ida Bagus Budhi
Session: e-Poster Display Session
329P - Radiotherapy palliative and COVID-19: Experience of radiotherapy oncology department of Cancer Center Tlemcen, Algeria
Presenter: Asma Mous
Session: e-Poster Display Session
330P - COVID and cancer: Choosing between hammer and anvil
Presenter: Ullas Batra
Session: e-Poster Display Session
331P - The clock stopped with COVID-19 but continued ticking for cancer patients
Presenter: Sasi Shanmugam Senga
Session: e-Poster Display Session
336P - Efficacy of methylcobalamin administered intravenously for chemotherapy-induced peripheral neuropathy (CIPN): A prospective crossover study
Presenter: Jun Chen
Session: e-Poster Display Session
337P - A prospective study about the quality of life and chemotherapy-induced peripheral neuropathy
Presenter: Wala Ben Kridis
Session: e-Poster Display Session
338P - Vitamin E in the treatment of chemotherapy and radiation-induced mucositis: A meta-analysis of randomized controlled trials
Presenter: Michelle Joane Alcantara
Session: e-Poster Display Session